SCHEMBL5699516

SCHEMBL5699516

CS(=O)(=O)OCCOC(CCOS(C)(=O)=O)COC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.36
PLA2G2A P14555 2/20 0.36
PLA2G10 O15496 1/20 0.36
PLA2G1B P04054 1/20 0.36
PLA2G5 P39877 1/20 0.36
CYP2C9 P11712 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
CYP2C19 P33261 1/20 0.34
TK1 P04183 3/20 0.34
DUT P33316 1/20 0.33
TK2 O00142 1/20 0.30
SLC6A1 P30531 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3623796 1.00 KIF11 (0.36) KIF11PLA2G2APLA2G10PLA2G1BPLA2G5
SCHEMBL4763266 0.91 DUT (0.40) KIF11PLA2G2APLA2G10PLA2G1BPLA2G5
SCHEMBL5699551 0.91 DUT (0.40) KIF11PLA2G2APLA2G10PLA2G1BPLA2G5
SCHEMBL8687134 0.91 KIF11 (0.39) KIF11PLA2G2APLA2G10PLA2G1BPLA2G5
SCHEMBL4762320 0.89 DUT (0.39) KIF11PLA2G2APLA2G10PLA2G1BPLA2G5
SCHEMBL4762322 0.89 DUT (0.39) KIF11PLA2G2APLA2G10PLA2G1BPLA2G5
SCHEMBL4193339 0.88 PLA2G2A (0.36) KIF11PLA2G2APLA2G10PLA2G1BPLA2G5
SCHEMBL4200031 0.83 KIF11 (0.33) KIF11PLA2G2APLA2G10PLA2G1BPLA2G5
SCHEMBL12714267 0.80 KIF11 (0.52) KIF11CYP2C9ALOX15TSHRCYP2C19
SCHEMBL16854613 0.80 PLA2G2A (0.50) KIF11PLA2G2APLA2G10PLA2G1BPLA2G5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1341927-B1 METHOD OF PREPARING 3-¬2-{(METHYLSULFONYL)OXY}ETHOXY|-4-(TRIPHENYLMETHOXY)-1-BUTANOL, METHANE SULFONATE PPG IND OHIO INC (US) 2006-08-02 EP claimed
EP-1341927-A1 METHOD OF PREPARING 3- 2- (METHYLSULFONYL)OXY ETHOXY]-4-(TRIPHENYLMETHOXY)-1-BUTANOL, METHANE SULFONATE PPG Industries Ohio, Inc. (US) 2003-09-10 EP claimed
WO-2002059342-A1 METHOD OF PREPARING 3-[2-{(METHYLSULFONYL)OXY}ETHOXY]-4-(TRIPHENYLMETHOXY)-1-BUTANOL, METHANE SULFONATE PPG INDUSTRIES OHIO, INC. (US) 2002-08-01 WO claimed
US-6300106-B1 FORMING S-ISOMER OR R-ISOMER OF (3,6-DIHYDRO-2H-PYRAN-2-YL)-METHANOL VIA A PROCESS WHICH PRODUCES A RACEMIC MIXTURE OF INTERMEDIATE REACTION PRODUCTS, RESOLVING TO SELECTIVELY PRODUCE S ISOMER PPG INDUSTRIES OHIO, INC. 2001-10-09 US claimed
US-20260042778-A1 Polymorphs of N-Desmethyl Ruboxistaurin and Salts Thereof 4M THERAPEUTICS INC. (US) 2026-02-12 US disclosed
EP-1341927-B1 METHOD OF PREPARING 3-¬2-{(METHYLSULFONYL)OXY}ETHOXY|-4-(TRIPHENYLMETHOXY)-1-BUTANOL, METHANE SULFONATE PPG IND OHIO INC (US) 2006-08-02 EP disclosed
EP-1341927-A1 METHOD OF PREPARING 3- 2- (METHYLSULFONYL)OXY ETHOXY]-4-(TRIPHENYLMETHOXY)-1-BUTANOL, METHANE SULFONATE PPG Industries Ohio, Inc. (US) 2003-09-10 EP disclosed
WO-2002059342-A1 METHOD OF PREPARING 3-[2-{(METHYLSULFONYL)OXY}ETHOXY]-4-(TRIPHENYLMETHOXY)-1-BUTANOL, METHANE SULFONATE PPG INDUSTRIES OHIO, INC. (US) 2002-08-01 WO disclosed
WO-2002059342-A1 METHOD OF PREPARING 3-[2-{(METHYLSULFONYL)OXY}ETHOXY]-4-(TRIPHENYLMETHOXY)-1-BUTANOL, METHANE SULFONATE PPG INDUSTRIES OHIO, INC. (US) 2002-08-01 WO disclosed
US-6300106-B1 FORMING S-ISOMER OR R-ISOMER OF (3,6-DIHYDRO-2H-PYRAN-2-YL)-METHANOL VIA A PROCESS WHICH PRODUCES A RACEMIC MIXTURE OF INTERMEDIATE REACTION PRODUCTS, RESOLVING TO SELECTIVELY PRODUCE S ISOMER PPG INDUSTRIES OHIO, INC. 2001-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042778-A1 Polymorphs of N-Desmethyl Ruboxistaurin and Salts Thereof GSK3B, GSK3A, LRRK2 KIF11 3811/4885PLA2G2A 4443/4885PLA2G10 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.